These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 7169836)
41. FDA insists on more women in drug trials. Josefson D BMJ; 1997 Oct; 315(7112):833. PubMed ID: 9353497 [No Abstract] [Full Text] [Related]
42. Good clinical practice in clinical drug trials--what you need to know. Soyebi K; Abosede ; Coker HA; Osuntoki ; Oyibos W; Keri H; Ogunsola S Nig Q J Hosp Med; 2008; 18(2):104-12. PubMed ID: 19068563 [No Abstract] [Full Text] [Related]
43. A look at the bioresearch monitoring program: the agency perspective. Brisson EL Food Drug Cosmet Law J; 1983 Apr; 38(2):184-9. PubMed ID: 11649578 [No Abstract] [Full Text] [Related]
44. FDA's perspective on women and drugs. Danello MA NIDA Res Monogr; 1986; 65():9-13. PubMed ID: 3090447 [No Abstract] [Full Text] [Related]
45. Innovative strategies for early clinical R&D. Butz RF; Morelli G IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261 [TBL] [Abstract][Full Text] [Related]
46. Drug development and the FDA's Critical Path Initiative. Woosley RL; Cossman J Clin Pharmacol Ther; 2007 Jan; 81(1):129-33. PubMed ID: 17186012 [TBL] [Abstract][Full Text] [Related]
47. The FDA's response to AIDS: paradigm shift in new drug policy? Podraza R Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267 [No Abstract] [Full Text] [Related]
48. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
49. Guidelines for the clinical evaluation of antianxiety drugs. HEW (FDA) 77-3043, September 1977. Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):297-312. PubMed ID: 45205 [No Abstract] [Full Text] [Related]
50. The FDA's restrictions against prescription drug advertising: more hindrance than help. Lorman AJ Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942 [No Abstract] [Full Text] [Related]
51. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule. Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458 [TBL] [Abstract][Full Text] [Related]
52. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
53. Growing AIDS "graveyard" placed at FDA's doorstep. Pollner F Med World News; 1988 Nov; 29(21):74-5. PubMed ID: 10290179 [No Abstract] [Full Text] [Related]
54. FDA's safety reform is greeted with scepticism. Moynihan R BMJ; 2005 Feb; 330(7489):435. PubMed ID: 15731128 [No Abstract] [Full Text] [Related]
55. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration. Feinsod M; Chambers WA Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539 [TBL] [Abstract][Full Text] [Related]
56. Drug industry trying to change FDA's slow but sure policy. Demkovich LE Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491 [No Abstract] [Full Text] [Related]
57. Is it time to abandon FDA's no release from liability regulation for clinical studies? Winter JD Food Drug Law J; 2008; 63(2):525-36. PubMed ID: 18561476 [No Abstract] [Full Text] [Related]
58. Clinical research in dentistry and the pharmaceutical industry. Economy DG Symp Pharmacol Ther Toxicol Group; 1975 Apr; ():32-7. PubMed ID: 775672 [No Abstract] [Full Text] [Related]
59. FDA's emergency research rule: an inch given, a yard taken. Gillenwater GE Food Drug Law J; 2008; 63(1):217-56. PubMed ID: 18561460 [No Abstract] [Full Text] [Related]
60. Applications of accelerator MS in pediatric drug evaluation. Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]